In the FAVOUR (NCT04858958, CTR20201697) phase Ib study, furmonertinib 240 mg once daily and 160 mg once daily both showed promising efficacy and a predictable and manageable safety profile in patients with NSCLC harboring EGFR Exon20ins mutations (20). This evidence concerns the gene EGFR and non-small cell lung carcinoma.